Results 281 to 290 of about 18,536,823 (334)
Establishment of Coala: a novel 3D and 2D cancer cell line derived from colorectal cancer liver metastasis. [PDF]
Mersakova S+33 more
europepmc +1 more source
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li+12 more
wiley +1 more source
Dissecting cell-free DNA fragmentation variation in tumors using cell line-derived xenograft mouse. [PDF]
Fu R+5 more
europepmc +1 more source
Trisomy 21 with 47,+18 lymphocyte cell line: double mitotic nondisjunction.
M B Jenkins+3 more
openalex +1 more source
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi+12 more
wiley +1 more source
Establishment and comparison of three sublines from a human uterine carcinosarcoma cell line, ESCA. [PDF]
Long Y+5 more
europepmc +1 more source
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza+3 more
wiley +1 more source
Cell line authentication and validation is a key requirement for <i>Journal of Cell Communication and Signaling</i> publications. [PDF]
Weiskirchen R, Almeida J, Chaqour B.
europepmc +1 more source
Hormone and neurotransmitter receptors in an established vascular endothelial cell line.
V. Buonassisi, J. Craig Venter
openalex +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source